Asthenia in advanced cancer and the use of psychostimulants
Keywords:
Fatiga. Astenia. Cáncer. Metilfenidato. Modafinilo.Abstract
Asthenia is the most frequent symptom in patients with advanced cancer and is probably what most affects the quality of life of oncology patients since it interferes in their physical and social activity. Treatment in the majority of cases is symptomatic. There is growing interest in the use of psychostimulants for treating asthenia. Methylphenidate and modafinil are two psychostimulants that have already been tested in controlled studies on asthenia of the patient with advanced cancer; they have proved to be efficient, particularly in patients in very advanced stages who are very tired.Downloads
References
1. SHARPE M, WILKS D. Fatigue. BMJ 2002; 325: 480-483.
https://doi.org/10.1136/bmj.325.7362.480
2. VOGELZANG NJ, BREITBART W, CELLA D, CURT GA, GROOPMAN JE, HORNING SJ et al. Patient, caregiver, and oncologist perceptions of cancer-related fatigue: results of a tripart assessment survey. The Fatigue coalition. Semin Hematol 1997; 34: 4-12.
3. CURT GA, BREITBART W, CELLA D, GROOPMAN JE, HORNING SJ, ITRI LM et al. Impact of cancer-related fatigue on the lives of patients: new findings from the Fatigue Coalition. Oncologist 2000; 5: 353-360.
https://doi.org/10.1634/theoncologist.5-5-353
4. GÓNZALEZ BARÓN M, FEYJÓO M, CARULLA TJ, CAMPS C, ESCOBAR Y, BELDA-INIESTA E. Study of the prevalence of tumor-related asthenia in Spanish cancer patients. Clin Transl Oncol 2008; 10: 351-358.
https://doi.org/10.1007/s12094-008-0211-z
5. CENTENO C, PORTELA MA, CARVAJAL A, SAN MIGUEL MT, URDIROZ J, RAMOS L et al. What is the best term in Spanish to express the concept of cancer-related fatigue? J Palliat Med 2009; 12: 441-445.
https://doi.org/10.1089/jpm.2008.0244
6. CELLA D, DAVIS K, BREITBART W, CURT G. Cancer-Related Fatigue: Prevalence of proposed diagnostic criteria in a United States sample of cancer survivors. J Clin Oncol 2001; 19: 3385-3391.
https://doi.org/10.1200/JCO.2001.19.14.3385
7. RADBRUCH L, STRESSER F, ELSNER F, GONZALVES JF, LOGE J, KAASA S et al. Fatigue in palliative care patients - an EAPC approach. Palliat Med 2008; 22: 13-32.
https://doi.org/10.1177/0269216307085183
8. BRUERA E, KUEHN N, MILLER MJ, SELMSER P, MACMILLAN K. The Edmonton Symptom Assessment System (ESAS): a simple method for the assessment of palliative care patients. J Palliat Care 1991; 7: 6-9.
https://doi.org/10.1177/082585979100700202
9. YELLEN SB, CELLA DF, WEBSTER K, BLENDOWSKI C, KAPLAN E. Measuring fatigue and others anemia-related symptoms with the Functional Assessment of Cancer Therapy (FACT) measurement system. J Pain Symtom Manage 1997; 13: 63-74.
https://doi.org/10.1016/S0885-3924(96)00274-6
10. RIZZO JD, BROUWERS M, HURLEY P, SEIDENFELD J, ARCASOY MO, SPIVACK JL et al. American Society of Clinical Oncology/American Society of Hematology clinical practice guideline update on the use of epoetin and darbepoetin in adult patients with cancer. J Clin Oncol 2010; 28: 4996-5010.
https://doi.org/10.1200/JCO.2010.29.2201
11. WANCHAI A, ARMER JM, STEWART BR. Nonpharmacologic supportive strategies to promote quality of life in patients experiencing cancer-related fatigue: a systematic review. Clin J Oncol Nurs 2011; 15: 203-214.
https://doi.org/10.1188/11.CJON.203-214
12. CRAMP F, DANIEL J. Exercise for the management of cancer - related fatigue in adults. Cochrane Database Syst Rev 2008; 16: CD006145.
https://doi.org/10.1002/14651858.CD006145.pub2
13. SPECK RM, COURNEYA KS, MÂSSE LC, DUVAL S, SCHMITZ KH. An update of controlled physical activity trials in cancer survivors: a systematic review and meta-analysis. J Cancer Surviv 2010; 4: 87-100.
https://doi.org/10.1007/s11764-009-0110-5
14. VELTHUIS MJ, AGASI-IDENBURG SC, AUFDEMKAMPE G, WITTINK HM. The effect of physical exercise on cancer-related fatigue during cancer treatment: a meta-analysis of randomised controlled trials. Clin Oncol (R Coll Radiol) 2010; 22: 208-221.
https://doi.org/10.1016/j.clon.2009.12.005
15. BROWN JC, HUEDO-MEDINA TB, PESCATELLO LS, PESCATELLO SM, FERRER RA, JOHNSON BT. Efficacy of exercise interventions in modulating cancer-related fatigue among adult cancer survivors: a meta-analysis. Cancer Epidemiol Biomarkers Prev 2011; 20: 123-133.
https://doi.org/10.1158/1055-9965.EPI-10-0988
16. DIMEO F. Radiotherapy-related fatigue and exercise for cancer patients: a review of the literature and suggestions for future research. Front Radiat Ther Onco 2002; 37: 49-56.
https://doi.org/10.1159/000061299
17. BRUERA E, ROCA E, CEDARO L, CARRARO S, CHACON R. Action of oral methylprednisolone in terminal cancer patients: a prospective randomized double-blind study. Cancer Treat Rep 1985; 69: 751-754.
18. BRUERA E, ERNST S, HAGEN N, SPACHYNSKI K, BELZILE M, HANSON J et al. Effectiveness of megestrol acetate in patients with advanced cancer: a randomized, double-blind, crossover study. Cancer Prev Control 1998; 2: 74-78.
19. BRUERA E, EL OSTA B, VALERO V, DRIVER LC, PEI BL, SHEN L et al. Donepezil for cancer fatigue. A double-blind, randomized, placebo-controlled trial. J Clin Oncol 2007; 25: 3475-3481.
https://doi.org/10.1200/JCO.2007.10.9231
20. STRASSER F, PALMER JL, SCHOVER LR, YUSUF SW, PISTERS K, VASSILOPOULOU-SELLIN R et al. The Impact of hypogonadism and autonomic dysfunction on fatigue, emotional function and sexual desire in male patients with advanced cancer. Cancer 2006; 107: 2949-2957.
https://doi.org/10.1002/cncr.22339
21. BRUERA E, NEUMANN CM, PITUSKIN E, CALDER K, BALL G, HANSON J et al. Thalidomide in patients with cachexia due to terminal cancer: preliminary report. Ann Oncol 1999; 10: 857-859.
https://doi.org/10.1023/A:1008329821941
22. BARTON DL, SOORI GS, BAUER BA, SLOAN JA, JOHNSON PA, Figueras C et al. Pilot study of Panax quinquefolius (American ginseng) to improve cancer-related fatigue: a randomized, double-blind, dose-finding evaluation: NCCTG trial N03CA. Support Care Cancer 2010; 18: 179-187.
https://doi.org/10.1007/s00520-009-0642-2
23. MINZENBERG MJ, CARTER CS. Modafinil: A review of neurochemical actions and effects on cognition: Neuropsychopharmacol 2008; 33: 1477-1502.
https://doi.org/10.1038/sj.npp.1301534
24. ENGBERG TM, DENNIS SA, JONES MS, MILLER MS, CONTRERAS PC. Brain regional substrates for the actions of the novel wake-promoting agent modafinil in the rat: comparison with amphetamine. Neuroscience 1998; 87: 905-911.
https://doi.org/10.1016/S0306-4522(98)00015-3
25. Real Decreto 1015/2009, de 19 de junio, por el que se regula la disponibilidad de medicamentos en situaciones especiales (BOE, 20 de julio).
26. BARRIOS FLORES LF. Nueva legislación en torno al uso compasivo del medicamento. Oncologyplus 2011; 1: 30-41.
27. MORASKA AR, SOOD A, DAKHIL SR, SLOAN JA, BARTON D, ATHERTON PJ et al. Phase III, randomized, double-blind, placebo-controlled study of long-acting methylphenidate for cancer-related fatigue: North Central Cancer Treatment group NCCTG-N05C7 Trial. J Clin Oncol 2010; 28: 3673-3679.
https://doi.org/10.1200/JCO.2010.28.1444
28. JEAN-PIERRE P, MORROW GR, ROSCOE JA, HECKLER CH, MOHILE S, JANELSINS M et al. A phase 3 randomized, placebo-controlled, double-blind, clinical trial of the effect of modafinil on cance-related fatigue among 631 patients receiving chemotherapy. Cancer 2010; 116: 3513-3520.
https://doi.org/10.1002/cncr.25083
29. YENNURAJALINGAM S, PALMER JL, CHACKO R, BRUERA E. Factors associated with response to methylphenidate in advanced cancer patients. Oncologist 2011; 16: 246-253.
https://doi.org/10.1634/theoncologist.2010-0214
30. LASHEEN W, WALSH D, MAHMOUD F, DAVIS MP, RIVERA N, KHOSHKNABI DS. Methylphenidate side effects in advanced cancer: a retrospective analysis. Am J Hosp Palliat Care 2010; 27: 16-23.
https://doi.org/10.1177/1049909109345145
31. KALEITA TA, WELLISCH DK, GRAHAM CA, STEH B, NGHIEMPHU P, FORD JM ET al. Pilot study of modafinil for treatment of neurobehavioral dysfunction and fatigue in adult patients with brain tumors. J Clin Oncol 2006; 24: 1503.
https://doi.org/10.1200/jco.2006.24.18_suppl.1503
32. LUNDORFF LE, JONSSON BH, SJOGREN P. Modafinil for attentional and psychomotor dysfunction in advanced cancer: a double-blind, randomised, cross-over trial. Palliat Med 2009; 23: 731-738.
https://doi.org/10.1177/0269216309106872
33. BRUERA E, VALERO V, DRIVER L, SHEN L, WILLEY J, ZHANG T et al. Patient-controlled methylphenidate for cancer fatigue: A double-blind, randomized, placebo- controlled trial. J Clin Oncol 2006; 24: 2073-2078.
https://doi.org/10.1200/JCO.2005.02.8506
34. BUTTLER JM, CASE LD, ATKINS J, FRIZZELL B, SANDERS G, GRIFFIN P et al. A phase III, double-blind, placebo-controlled prospective randomized clinical trial of d-threo-methylphenidate HCI in brain tumor patients receiving radiation therapy. Int J Radiat Oncol Biol Phys 2007; 69: 1496-1501.
https://doi.org/10.1016/j.ijrobp.2007.05.076
35. MAR FAN HG, CLEMONS M, XU W, CHEMERYNSKY I, BREUNIS H, BRAGANZA S et al. A randomized, placebo-controlled, double-blind trial of the effects of d-methylphenidate on fatigue and cognitive dysfunction in women undergoing adjuvant chemotherapy for breast cancer. Support Care Cancer 2008; 16: 577-583.
https://doi.org/10.1007/s00520-007-0341-9
36. LOWER EE, FLEISHMAN S, COOPER A, ZELDIS J, FALECK H, YU Z et al. Efficacy of dexmethylphenidate for the treatment of fatigue after cancer chemotherapy: a randomized clinical trial. J Pain Symptom Manage 2009; 38: 650-662.
https://doi.org/10.1016/j.jpainsymman.2009.03.011
37. ROTH AJ, NELSON C, ROSENFELD B, SCHER H, SLOVIN S, MORRIS M et al. Methylphenidate for fatigue in ambulatory men with prostate cancer. Cancer 2010; 116: 5102-5110.
Downloads
Published
How to Cite
Issue
Section
License
Copyright (c) 2012 Anales del Sistema Sanitario de Navarra
This work is licensed under a Creative Commons Attribution-ShareAlike 4.0 International License.
La revista Anales del Sistema Sanitario de Navarra es publicada por el Departamento de Salud del Gobierno de Navarra (España), quien conserva los derechos patrimoniales (copyright ) sobre el artículo publicado y favorece y permite la difusión del mismo bajo licencia Creative Commons Reconocimiento-CompartirIgual 4.0 Internacional (CC BY-SA 4.0). Esta licencia permite copiar, usar, difundir, transmitir y exponer públicamente el artículo, siempre que siempre que se cite la autoría y la publicación inicial en Anales del Sistema Sanitario de Navarra, y se distinga la existencia de esta licencia de uso.
